
Organovo Holdings ONVO
Quarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Total Assets 2011-2026 | ONVO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 M | 6.35 M | 20.3 M | 39.9 M | 28.4 M | 40.6 M | 49.8 M | 69.2 M | 67.6 M | 53.5 M | 50.2 M | 17.4 M | 16.7 M | 4.28 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.2 M | 4.28 K | 33.9 M |
Quarterly Total Assets Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.96 M | 9.69 M | 12 M | 14.6 M | 3.84 M | 6.75 M | 9.47 M | 6.35 M | 8.88 M | 11.2 M | 14.8 M | 20.3 M | 25.1 M | 27.9 M | 30.5 M | 33.3 M | 35.1 M | 35.9 M | 38.3 M | 39.9 M | 21.6 M | 20.6 M | 25.6 M | 28.4 M | 31.3 M | 37.8 M | 43.5 M | 40.6 M | 39.7 M | 42.6 M | 45.1 M | 49.8 M | 53.6 M | 56.9 M | 61.7 M | 69.2 M | 76.1 M | 57.5 M | 58.8 M | 67.6 M | 74.5 M | 81.7 M | 90.6 M | 53.5 M | 52.1 M | 56.5 M | 46.9 M | 50.2 M | 51.6 M | 54.9 M | 14.5 M | 17.4 M | 16.7 M | 9.04 M | 9.71 M | 11.2 M | 1.41 M | 1.41 M | 1.41 M | 1.41 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90.6 M | 1.41 M | 33.6 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.3 | 0.62 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
97.2 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.2 | 0.33 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
413 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 2.59 | 1.57 % | $ 84.1 K | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
73.6 M | $ 1.15 | -4.17 % | $ 6.26 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Celcuity
CELC
|
467 M | $ 114.22 | 1.41 % | $ 5.34 B | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 192.12 | 0.53 % | $ 137 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
6.34 B | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.96 | 0.91 % | $ 22.1 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.42 | -2.38 % | $ 496 M | ||
|
Guardant Health
GH
|
2.01 B | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.97 | 0.63 % | $ 8.72 M | ||
|
Illumina
ILMN
|
6.3 B | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
29.9 B | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
National Research Corporation
NRC
|
135 M | $ 17.33 | 0.99 % | $ 388 M |